Hydroxychloroquine as postexposure prophylaxis for Covid-19

Michael S. Avidan; Hakim Moulay Dehbi; Sinead Delany-Moretlwe

doi:10.1056/NEJMc2023617

Hydroxychloroquine as postexposure prophylaxis for Covid-19

Michael S. Avidan, Hakim Moulay Dehbi, Sinead Delany-Moretlwe

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	1087-1088
Number of pages	2
Journal	New England Journal of Medicine
Volume	383
Issue number	11
DOIs	https://doi.org/10.1056/NEJMc2023617
State	Published - Sep 10 2020

Access to Document

10.1056/NEJMc2023617

Cite this

@article{f0e68d22399e4d31bb6641852d44be4a,

title = "Hydroxychloroquine as postexposure prophylaxis for Covid-19",

author = "Avidan, {Michael S.} and Dehbi, {Hakim Moulay} and Sinead Delany-Moretlwe",

note = "Funding Information: Supported by grants from the AIDS Healthcare Foundation, the Doris Duke Charitable Foundation (2019086), the National Institutes of Health (AI124979, AI131879, AI140775, AI068616, AI068632, and AI106716), the James B. Pendleton Charitable Trust, and the McCarthy Family Foundation. Funding Information: Dr. Tekwani reports receiving support to his laboratory from the collaborative Antiviral Drug Discovery and Development Center, which is led by the University of Alabama at Birmingham School of Medicine and funded by a Centers of Excellence for Translational Research grant (U19 AI142759) from the NIAID. No other potential conflict of interest relevant to this letter was reported.",

year = "2020",

month = sep,

day = "10",

doi = "10.1056/NEJMc2023617",

language = "English",

volume = "383",

pages = "1087--1088",

journal = "New England Journal of Medicine",

issn = "0028-4793",

number = "11",

}

TY - JOUR

T1 - Hydroxychloroquine as postexposure prophylaxis for Covid-19

AU - Avidan, Michael S.

AU - Dehbi, Hakim Moulay

AU - Delany-Moretlwe, Sinead

N1 - Funding Information: Supported by grants from the AIDS Healthcare Foundation, the Doris Duke Charitable Foundation (2019086), the National Institutes of Health (AI124979, AI131879, AI140775, AI068616, AI068632, and AI106716), the James B. Pendleton Charitable Trust, and the McCarthy Family Foundation. Funding Information: Dr. Tekwani reports receiving support to his laboratory from the collaborative Antiviral Drug Discovery and Development Center, which is led by the University of Alabama at Birmingham School of Medicine and funded by a Centers of Excellence for Translational Research grant (U19 AI142759) from the NIAID. No other potential conflict of interest relevant to this letter was reported.

PY - 2020/9/10

Y1 - 2020/9/10

UR - http://www.scopus.com/inward/record.url?scp=85090870001&partnerID=8YFLogxK

U2 - 10.1056/NEJMc2023617

DO - 10.1056/NEJMc2023617

M3 - Letter

C2 - 32668106

AN - SCOPUS:85090870001

SN - 0028-4793

VL - 383

SP - 1087

EP - 1088

JO - New England Journal of Medicine

JF - New England Journal of Medicine

IS - 11

ER -

Hydroxychloroquine as postexposure prophylaxis for Covid-19

Access to Document

Other files and links

Cite this